Fact based stock research
GW Pharmapeuticals (NasdaqGM:GWPH)

US36197T1034



Research has been discontinued. Contact us if you want research on this stock.



GW Pharmapeuticals stock research in summary

gwpharm.com


There is no stock research analysis by the purely financial fact-based Obermatt method for: GW Pharmapeuticals (NasdaqGM:GWPH), Pharmaceuticals, United Kingdom. Contact us if you would like research on this stock.


Latest Obermatt Ranks


Value Rank n/a
Growth Rank n/a
Safety Rank n/a
Combined Rank n/a
Country United Kingdom
Industry Pharmaceuticals
Index
Size class X-Small

January 1, 2000. Stock data may be delayed. Login to get the most recent research.

Add to Watchlist
Filter Similar Stocks
Similar Top 10

Research History: GW Pharmapeuticals

RESEARCH HISTORY 2019 2020 2021 2022
VALUE
VALUE n/a
n/a
n/a
n/a
GROWTH
GROWTH n/a
n/a
n/a
n/a
SAFETY
SAFETY n/a
n/a
n/a
n/a
COMBINED
COMBINED n/a
n/a
n/a
n/a

Last update of Combined Rank: . Financial reporting date used for calculating ranks: . Stock research history is based on the Obermatt Method. The higher the rank, the better GW Pharmapeuticals is in the corresponding investment strategy.


Value Metrics in Detail

VALUE METRICS 2019 2020 2021 2022
PRICE VS. REVENUES (P/S)
PRICE VS. REVENUES (P/S) n/a
n/a
n/a
n/a
PRICE VS. PROFITS (P/E)
PRICE VS. PROFITS (P/E) n/a
n/a
n/a
n/a
PRICE VS. CAPITAL (Market-to-Book)
PRICE VS. CAPITAL (Market-to-Book) n/a
n/a
n/a
n/a
DIVIDEND YIELD
DIVIDEND YIELD n/a
n/a
n/a
n/a
CONSOLIDATED RANK: VALUE
CONSOLIDATED RANK: VALUE n/a
n/a
n/a
n/a

Last update of Value Rank: . Stock analysis on value ratios: The higher the rank, the lower the value ratio of GW Pharmapeuticals; except for dividend yield where the rank is higher, the higher the yield.


Growth Metrics in Detail

GROWTH METRICS 2019 2020 2021 2022
REVENUE GROWTH
REVENUE GROWTH n/a
n/a
n/a
n/a
PROFIT GROWTH
PROFIT GROWTH n/a
n/a
n/a
n/a
STOCK RETURNS
STOCK RETURNS n/a
n/a
n/a
n/a
CONSOLIDATED RANK: GROWTH
CONSOLIDATED RANK: GROWTH n/a
n/a
n/a
n/a

Last update of Growth Rank: . Stock analysis on growth metrics: The higher the rank, the higher the growth and returns of GW Pharmapeuticals.


Safety Metrics in Detail

SAFETY METRICS 2019 2020 2021 2022
LEVERAGE
LEVERAGE n/a
n/a
n/a
n/a
REFINANCING
REFINANCING n/a
n/a
n/a
n/a
LIQUIDITY
LIQUIDITY n/a
n/a
n/a
n/a
CONSOLIDATED RANK: SAFETY
CONSOLIDATED RANK: SAFETY n/a
n/a
n/a
n/a

Last update of Safety Rank: . Stock analysis on safety metrics: The higher the rank, the lower the leverage of GW Pharmapeuticals and the more cash is available to service its debt.


Stock analysis by the purely financial fact-based Obermatt Method for the investment strategies Value, Growth and Safety for GW Pharmapeuticals from January 1, 2000.


We invest in our stock tips ourselves and openly publish the returns of our portfolio. That's how much we believe in our stock research. Subscribe to the top 10 stocks for 100 markets conveniently by e-mail.